Prosecution Insights
Last updated: April 19, 2026

Examiner: KENNEDY, SARAH JANE

Tech Center 1600 • Art Units: 1682

This examiner grants 0% of resolved cases

Performance Statistics

%
Allow Rate
-60.0% vs TC avg
60
Total Applications
+0.0%
Interview Lift
1175
Avg Prosecution Days
Based on 5 resolved cases, 2023–2026

Rejection Statute Breakdown

16.2%
§101 Eligibility
7.2%
§102 Novelty
44.8%
§103 Obviousness
20.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18008953 COMPOSITIONS AND METHODS FOR SEQUENCING USING AT LEAST ELECTRICAL CHARACTERISTICS Final Rejection Illumina, Inc.
18010188 Selective Addition of Reagents to Droplets Final Rejection The Regents of the University of California
17768700 COMPOSITIONS AND METHODS FOR TEMPORAL CONTROL OF CELL MODULATION Final Rejection The Regents of the University of California
17633922 COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF BLADDER CANCER Final Rejection The Regents of the University of California
18183818 COMPOSITIONS AND METHODS FOR DETECTING FUSION GENES Non-Final OA Singular Genomics Systems, Inc.
17738538 CONTROLLED CROSSLINKING OF BIOMOLECUES IN SITU Non-Final OA 10x Genomics, Inc.
18180733 ANALYTE DETECTION SYSTEMS AND METHODS OF USE Final Rejection Nautilus Subsidiary, Inc.
17721686 ENHANCED DETECTION SENSITIVITY WITHIN CONJUGATE-BINDING ASSAYS Non-Final OA DENSO CORPORATION
17594119 MARKERS OF EFFICACY OF TOPOISOMERASE POISONS Non-Final OA Northwestern University
17772782 ON-CHIP ASSAY STRATEGY FOR THE DEVELOPMENT OF ELECTROCHEMICAL READOUT FOR CRISPR-CAS DIAGNOSTICS Final Rejection MASSACHUSETTS INSTITUTE OF TECHNOLOGY
18268240 METHODS OF CANCER DETECTION USING EXTRAEMBRYONICALLY METHYLATED CPG ISLANDS Non-Final OA DANA-FARBER CANCER INSTITUTE, INC.
17761040 COMPOSITIONS AND METHODS FOR TREATMENT OF A POOR PROGNOSIS SUBTYPE OF COLORECTAL CANCER Final Rejection DANA-FARBER CANCER INSTITUTE, INC.
17639532 RAPID PREDICTION OF DRUG RESPONSIVENESS Final Rejection DANA-FARBER CANCER INSTITUTE, INC.
18271793 PREDICTION OF AN OUTCOME OF A COLORECTAL CANCER SUBJECT Non-Final OA KONINKLIJKE PHILIPS N.V.
18281068 MARKERS SPECIFIC FOR PLURIPOTENT STEM CELLS, AND METHODS OF USING THE SAME Non-Final OA FUJIFILM CELLULAR DYNAMICS, INC.
17801677 APPARATUS AND METHOD FOR RAPID MONITORING OF PATHOGENS IN WATER Final Rejection CRANFIELD UNIVERSITY
18015051 COMPOSITIONS AND METHODS FOR DETECTION OF LUNG CANCER Final Rejection Mercy BioAnalytics, Inc.
17807822 RAPID AND SAMPLE-SPECIFIC DETECTION OF VIRAL PATHOGEN FOR POOLED TESTING IN LARGE-POPULATION SCREENING Non-Final OA THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY
17922589 METHOD AND MARKERS FOR IDENTIFICATION AND RELATIVE QUANTIFICATION OF NUCLEIC ACID SEQUENCE, MUTATION, COPY NUMBER, OR METHYLATION CHANGES USING COMBINATIONS OF NUCLEASE, LIGATION, DEAMINATION, DNA REPAIR, AND POLYMERASE REACTIONS WITH CARRYOVER PREVENTION Non-Final OA CORNELL UNIVERSITY
17691277 Methods for Predicting Treatment Response in Ulcerative Colitis Non-Final OA Janssen Biotech, Inc.
18481306 METHODS FOR SCREENING A SUBJECT FOR A CANCER Non-Final OA UNIVERSITE DE MONTPELLIER
18041131 MULTIOMIC ANALYSIS OF NANOPARTICLE-CORONAS Non-Final OA THE UNIVERSITY OF MANCHESTER
18016153 IDENTIFICATION OF GENOME REGIONS ASSOCIATED WITH KIDNEY DISEASE AND TREATMENT Final Rejection THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
17797680 NUCLEIC ACID SEQUENCE DETECTION BY ENDONUCLEASE DIGESTION AND MASS SPECTROMETRY Final Rejection Chan Zuckerberg Biohub, Inc.
18009945 METHODS FOR DETECTING AND PREDICTING CANCER AND/OR CIN3 Non-Final OA UCL Business Ltd
18017432 MCI DIAGNOSTIC MARKER, MCI DIAGNOSTIC KIT AND CORRESPONDING DETECTION METHOD Final Rejection SHANGHAI MENTAL HEALTH CENTER (SHANGHAI PSYCHOLOGICAL COUNSELLING TRAINING CENTER)
17634444 METHODS FOR GENERATING A POPULATION OF POLYNUCLEOTIDE MOLECULES Final Rejection QUEEN MARY UNIVERSITY OF LONDON
18264077 METHODS TO DETECT AND TREAT A FUNGAL INFECTION Non-Final OA THE U.S. GOVERNMENT AS REPRESENTED BY THE DEPT. OF VETERAN AFFAIRS
18274888 LIQUID COMPOSITION FOR MOLECULAR DIAGNOSTICS BY PCR Non-Final OA BIOINOVA, A.S.
17403480 TAGGED-BASE DNA SEQUENCING READOUT ON WAVEGUIDE SURFACES Non-Final OA SiPhox, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month